Skip to main content

Treatment Clinical Trials for Central Nervous System Embryonal Neoplasm

Review the central nervous system embryonal neoplasm treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-8 of 8

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Status: Active
Location: 106 locations
Digoxin for the Treatment of Pediatric and Young Adult Patients with Relapsed Non-SHH, Non-WNT Medulloblastoma
Status: Active
Location: 9 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 6 locations
Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors
Status: Active
Location: 2 locations
Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial
Status: Active
Location: 2 locations
Liothyronine in Combination with Bevacizumab, Irinotecan and Temozolomide for the Treatment of Children and Young Adults with Progressive or Relapsed Medulloblastoma or Medulloblastoma with Minimal Residual Disease
Status: Active
Location: 2 locations
PEP-CMV Vaccine plus Nivolumab for the Treatment of Newly Diagnosed or Recurrent Childhood Diffuse Midline Glioma/High-Grade Glioma and Recurrent Childhood Medulloblastoma and Ependymoma, PRiME II Trial
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 11 locations